Journal of clinical and experimental hematopathology : JCEH最新文献_第2页

Adult T-cell leukaemia/lymphoma with different histological features in a single lymph node. 成人t细胞白血病/淋巴瘤在单个淋巴结中具有不同的组织学特征。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-06-28 Epub Date: 2026-04-28 DOI: 10.3960/jslrt.26003

Hiroko Muta, Reiji Muto, Naoko Harada, Hiroaki Miyoshi

{"title":"Adult T-cell leukaemia/lymphoma with different histological features in a single lymph node.","authors":"Hiroko Muta, Reiji Muto, Naoko Harada, Hiroaki Miyoshi","doi":"10.3960/jslrt.26003","DOIUrl":"10.3960/jslrt.26003","url":null,"abstract":"We report a case of adult T-cell leukaemia/lymphoma (ATLL) that exhibited different pathological subtypes within a single lymph node. The patient was a 76-year-old Japanese man who presented with decreased appetite and anemia, and a thorough examination was conducted. A peripheral blood analysis and imaging studies, including ultrasound and computed tomography, suggested malignant lymphoma, and cervical lymph node biopsy was subsequently performed.In the excised lymph node, the normal architecture was completely effaced, and areas showing the dense proliferation of pleomorphic atypical lymphocytes-consistent with the most common histology of ATLL (pleomorphic cell variant)-were identified. Regions exhibiting features reminiscent of classic Hodgkin lymphoma and others resembling angioimmunoblastic T-cell lymphoma were also observed. Serological testing was positive for human T-lymphotropic virus type 1 antibodies, and together with histological findings, this case was diagnosed as ATLL.To the best of our knowledge, there have been no cases exhibiting different histological patterns within a single lymph node.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"130-135"},"PeriodicalIF":1.4,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147794636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review. 莫舒尼妥珠单抗治疗以乳糜胸为表现的复发性滤泡性淋巴瘤：1例报告和文献复习。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-06-28 Epub Date: 2026-05-25 DOI: 10.3960/jslrt.26025

Ken Naganuma, Kumi Hirata, Yuta Arai, Soshi Tezuka, Takeaki Matsunaga, Taisuke Kawada, Noriyuki Sakata, Yasuyuki Takahashi, Takahisa Yamashita, Shuji Momose, Morihiro Higashi, Takayuki Tabayashi

{"title":"Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.","authors":"Ken Naganuma, Kumi Hirata, Yuta Arai, Soshi Tezuka, Takeaki Matsunaga, Taisuke Kawada, Noriyuki Sakata, Yasuyuki Takahashi, Takahisa Yamashita, Shuji Momose, Morihiro Higashi, Takayuki Tabayashi","doi":"10.3960/jslrt.26025","DOIUrl":"10.3960/jslrt.26025","url":null,"abstract":"Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma characterized by a relapsing clinical course. Recently, CD20×CD3 bispecific antibodies, including mosunetuzumab, have emerged as effective therapeutic options for relapsed or refractory FL. However, their efficacy in malignant effusions, including pleural effusion, remains unclear. We report a case of relapsed FL complicated by chylothorax that showed a rapid response to mosunetuzumab. A 74-year-old woman with a history of FL, initially treated with R-CHOP and later with rituximab monotherapy, presented with progressive dyspnea and was found to have bilateral pleural effusion. Analysis of pleural fluid revealed chylothorax with infiltration of CD20-positive lymphoma cells, confirmed by flow cytometry and cell-block immunohistochemistry. Following initiation of mosunetuzumab, pleural effusion decreased promptly, with a marked reduction in lymphoma cells in the pleural fluid observed as early as day 2. The patient achieved a complete metabolic response on positron emission tomography-computed tomography (PET-CT) after eight cycles of therapy. This case suggests that mosunetuzumab may exert rapid antitumor activity in both systemic disease and malignant effusions, possibly through distribution into pleural fluid and subsequent T-cell-mediated cytotoxicity. Further studies are warranted to clarify the role of bispecific antibodies in malignant effusions associated with lymphoma.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"166-172"},"PeriodicalIF":1.4,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148020480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-marketing surveillance of tirabrutinib for Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma in Japan. 替拉替尼在日本治疗Waldenström巨球蛋白血症/淋巴浆细胞性淋巴瘤的上市后监测

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-06-28 Epub Date: 2026-03-16 DOI: 10.3960/jslrt.25054

Akira Kawasaki, Toshikazu Nagano, Yudai Higuchi, Ryo Nishikawa, Koji Izutsu

{"title":"Post-marketing surveillance of tirabrutinib for Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma in Japan.","authors":"Akira Kawasaki, Toshikazu Nagano, Yudai Higuchi, Ryo Nishikawa, Koji Izutsu","doi":"10.3960/jslrt.25054","DOIUrl":"10.3960/jslrt.25054","url":null,"abstract":"Tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, was approved in Japan in August 2020 for the treatment of Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL). We report the findings of post-marketing surveillance (PMS) of tirabrutinib that was started following its approval. We conducted an all-case PMS of patients who started tirabrutinib treatment between August 21, 2020, and January 17, 2021, for WM/LPL in Japan. Safety and effectiveness data were recorded for up to 52 weeks after the first dose of tirabrutinib. Among 152 patients who started tirabrutinib, 67.1% were male, 77.6% were ≥ 65 years old, and 61.8% started treatment with tirabrutinib at 480 mg/day (once-daily). Among these 152 patients, any-grade and grade ≥ 3 adverse drug reactions (ADRs) occurred in 58.6% and 29.6% of patients, respectively. The main ADRs were platelet count decreased (9.2%) and rash (9.2%). Grade 5 ADRs were reported in four patients (2.6%). The outcomes of most ADRs associated with the safety specifications (myelosuppression, infections, interstitial lung diseases, clinically significant skin disorders, hemorrhages, hepatic function disorders, and hypersensitivities) were resolved or improved. The effectiveness was assessed by the physicians using the VIth International Workshop for Waldenström's Macroglobulinemia criteria. Among 85 patients (initial dose: 480 mg/day) included in the effectiveness analysis set, the major response and overall response rates were 63.5% and 74.1%, respectively. This PMS suggested that the safety profile of tirabrutinib for patients with WM/LPL in real-world clinical settings is in line with that observed in prior studies.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"111-121"},"PeriodicalIF":1.4,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147464755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasmablastic lymphoma through clonal expansion 17 years after EBV-positive DLBCL: case report and review. ebv阳性DLBCL后17年克隆扩增的浆母细胞淋巴瘤：病例报告和回顾。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-06-28 Epub Date: 2026-05-30 DOI: 10.3960/jslrt.26012

Keita Ishii, Yasuhiro Arakawa, Kazuhito Suzuki, Masaharu Kawashima, Shingo Yano

{"title":"Plasmablastic lymphoma through clonal expansion 17 years after EBV-positive DLBCL: case report and review.","authors":"Keita Ishii, Yasuhiro Arakawa, Kazuhito Suzuki, Masaharu Kawashima, Shingo Yano","doi":"10.3960/jslrt.26012","DOIUrl":"10.3960/jslrt.26012","url":null,"abstract":"Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of B-cell lymphoma associated with immunodeficiency and Epstein-Barr virus (EBV) infection. Although PBL can develop from indolent lymphomas, its occurrence long after diffuse large B-cell lymphoma (DLBCL) is rare. A 67-year-old man was diagnosed with EBV-positive DLBCL 17 years ago and achieved a sustained remission following six cycles of R-CHOP therapy. Seventeen years after the initial DLBCL diagnosis, the patient developed PBL with EBV-positive tumor cells. After three cycles of EPOCH therapy, the patient achieved a partial response and underwent upfront autologous stem cell transplantation, resulting in complete remission. To investigate the clonal relationship between DLBCL and PBL, immunoglobulin gene repertoire analysis using next-generation sequencing was performed on both specimens. In the PBL specimen, immunoglobulin heavy chain rearrangement revealed a dominant clone with a complementarity-determining region 3 (CDR3) length of 38 amino acids. Although the DLBCL specimen lacked a dominant clone meeting the clonality criteria, a minor clone with a CDR3 sequence similar to that of the PBL dominant clone was detected. This clone exhibited an unusually long CDR3 sequence (37 amino acids), likely contained stop codons, and was considered a nonfunctional clone. These findings suggest that PBL originated through expansion of a pre-existing minor subclone that persisted since the initial DLBCL diagnosis, driven by long-term clonal dynamics. Our case highlights the potential utility of immunoglobulin repertoire analysis in identifying clonal relationships among lymphomas, supporting treatment decisions, and understanding the pathogenesis of secondary lymphomas.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"148-155"},"PeriodicalIF":1.4,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suggestive characteristic change of CD123⁺dendritic cells in Kikuchi-Fujimoto Disease. 菊池-藤本病中CD123+树突状细胞的特征性改变。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-06-28 Epub Date: 2026-04-28 DOI: 10.3960/jslrt.26001

Shigeyuki Asano, Kikuo Mori, Kazuki Yamazaki, Hiroko Sato, Hiroyuki Naito, Rin Yamada, Yoshihiro Komohara

引用次数: 0

Efficacy and safety of Pola-R-mini-CHP therapy in patients aged ≥80 years with CD5-positive diffuse large B-Cell lymphoma. Pola-R-mini-CHP治疗≥80岁cd5阳性弥漫性大b细胞淋巴瘤患者的疗效和安全性

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-03-31 Epub Date: 2025-12-24 DOI: 10.3960/jslrt.25066

Kosuke Arai, Yasunobu Sekiguchi, Shizuka Hamano, Hiroki Tsutsumi, Masahisa Kudo, Nobuo Maseki, Yoshie Iizaki, Machiko Kawamura, Kazuhiko Kobayashi, Yu Nishimura, Hiroaki Kanda, Daisuke Takei, Tomoya Abe, Makoto Hanai, Sayaka Endo, Yu Kakusaka, Toshiaki Nakayama, Yasumasa Shimano, Hirofumi Kobayashi

引用次数: 0

Primary gastric EBV-positive cytotoxic-molecule-negative T-cell lymphoma with TET2 multihit mutations: a case report. 原发性胃ebv阳性细胞毒-分子阴性t细胞淋巴瘤伴TET2多击突变1例。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-03-31 Epub Date: 2026-01-20 DOI: 10.3960/jslrt.25075

Masako Kurashige, Akihisa Hino, Koki Muto, Keisuke Nagahama, Takehiro Yamamoto, Keiichi Nakata, Michiko Ichii, Kentaro Fukushima, Kennosuke Karube, Yasuhito Nannya, Naoki Hosen, Seishi Ogawa, Eiichi Morii

{"title":"Primary gastric EBV-positive cytotoxic-molecule-negative T-cell lymphoma with TET2 multihit mutations: a case report.","authors":"Masako Kurashige, Akihisa Hino, Koki Muto, Keisuke Nagahama, Takehiro Yamamoto, Keiichi Nakata, Michiko Ichii, Kentaro Fukushima, Kennosuke Karube, Yasuhito Nannya, Naoki Hosen, Seishi Ogawa, Eiichi Morii","doi":"10.3960/jslrt.25075","DOIUrl":"10.3960/jslrt.25075","url":null,"abstract":"Extranodal NK/T-cell lymphoma (ENKTL) is an Epstein-Barr virus (EBV)-positive lymphoma of the NK- or cytotoxic T-cell lineage. According to the World Health Organization Classification of Hematolymphoid Tumors, Fifth Edition (WHO-HAEM5), EBV-positive cases lacking cytotoxic molecules cannot be classified as ENKTL. To the best of our knowledge, this is the first documented case of primary gastric EBV-positive T-cell lymphoma lacking the expression of cytotoxic molecules. A 76-year-old woman initially presented with a disease confined to the stomach, with subsequent contiguous extension into the duodenum. Biopsies revealed small- to medium-sized atypical T cells with pale cytoplasm and irregularly folded nuclei, as well as intravascular infiltration. Tumor cells were positive for CD3, TCRβF1, and CD4 and negative for CD56, TIA-1, granzyme B, perforin, and PD-L1. EBV-encoded RNA in situ hybridization highlighted neoplastic T cells. These findings did not fulfill the criteria for any T/NK cell entity of WHO-HAEM5 including ENKTL and peripheral T-cell lymphoma not otherwise specified (PTCL, NOS). Targeted sequencing revealed TET2 multihit mutations, suggesting clonal hematopoiesis-linked pathogenesis. Given the patient's age and tumor location, we administered a reduced dose of DeVIC, followed by radiotherapy, achieving partial remission. This case expands the spectrum of EBV-associated T-cell lymphomas and highlights the need for additional cases to refine the classification and management.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"85-90"},"PeriodicalIF":1.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13160649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful cord blood transplantation for a unique mature γδ T-cell leukemia with KMT2A::AFDN translocation. 成功的脐带血移植治疗KMT2A::AFDN易位的独特成熟γδ t细胞白血病。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-03-31 Epub Date: 2026-01-28 DOI: 10.3960/jslrt.25063

Satoshi Ichikawa, Shunsuke Hatta, Koichi Onodera, Tohru Fujiwara, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

引用次数: 0

Composite lymphoma comprising adult T-cell leukemia/lymphoma and Epstein-Barr virus-positive primary central nervous system lymphoma. 复合淋巴瘤包括成人t细胞白血病/淋巴瘤和爱泼斯坦-巴尔病毒阳性原发性中枢神经系统淋巴瘤。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-03-31 Epub Date: 2026-01-28 DOI: 10.3960/jslrt.25069

Kohtaro Toyama, Genya Yoshida, Manato Sugisaki, Hisashi Takei, Takatomo Yoshida

{"title":"Composite lymphoma comprising adult T-cell leukemia/lymphoma and Epstein-Barr virus-positive primary central nervous system lymphoma.","authors":"Kohtaro Toyama, Genya Yoshida, Manato Sugisaki, Hisashi Takei, Takatomo Yoshida","doi":"10.3960/jslrt.25069","DOIUrl":"10.3960/jslrt.25069","url":null,"abstract":"A 73-year-old woman presented with cervical lymphadenopathy. A biopsy of the affected lymph node showed the diagnosis of adult T-cell leukemia/lymphoma (ATLL). While treatment was planned, she developed rapid-onset consciousness disturbance and gait disorder 1 week before the initiation of therapy, leading to emergency hospitalization. Computed tomography showed a hypodense lesion in the midbrain, and a cerebrospinal fluid analysis showed ATLL cells, resulting in a diagnosis of central nervous system infiltration of ATLL. High-dose methotrexate plus cytarabine therapy was administered. However, this therapy was ineffective, and the patient died on hospital day 21. An autopsy showed that the midbrain tumor was an Epstein-Barr virus-positive primary central nervous system lymphoma. Although there have been reports of primary central nervous system lymphoma developing during the treatment course of ATLL, to the best of our knowledge, this is the first reported case of concurrent onset of both diseases.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"66 1","pages":"75-79"},"PeriodicalIF":1.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13160654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147597709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient. CD19 CAR - t细胞治疗复发/难治性弥漫性大b细胞淋巴瘤1例90岁患者

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2026-03-31 Epub Date: 2026-02-28 DOI: 10.3960/jslrt.25070

Jotaro Yamamoto, Daisuke Kaji, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida, Go Yamamoto

{"title":"CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient.","authors":"Jotaro Yamamoto, Daisuke Kaji, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida, Go Yamamoto","doi":"10.3960/jslrt.25070","DOIUrl":"10.3960/jslrt.25070","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of relapsed/refractory large B-cell lymphoma. However, evidence in the ultra-elderly population remains scarce. We report a 90-year-old woman with relapsed/refractory diffuse large B-cell lymphoma transformed from follicular lymphoma who received lisocabtagene maraleucel. Despite advanced age, preserved cognition, intact instrumental activities of daily living, and acceptable organ reserve supported her candidacy for CAR T-cell therapy. Cytokine release syndrome (CRS) developed as grade 1 (day 1, 38.0 °C) and grade 2 (day 3, hypoxemia to 6 L/min), which resolved after early tocilizumab and dexamethasone. No immune effector cell-associated neurotoxicity syndrome or infectious complications occurred. Grade 2-4 cytopenia persisted transiently but was managed with supportive care, and she was discharged on day 28. To our knowledge, this represents the first reported case of a nonagenarian Asian patient successfully treated with CAR T-cell therapy, highlighting the feasibility and tolerability of this approach and emphasizing the importance of geriatric assessment and prompt CRS management for safe delivery in the very elderly.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"80-84"},"PeriodicalIF":1.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13160650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147328904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0